REMARKS

Amendments to the specification have been made to correct typographical and minor mathematical errors.

At page 21, line 25, "2.4" has been amended to read "2.3". Together with further amendment of lines 24 - 25 to read that *E. coli* derived non-glycosylated TFPI and ANV are 2.3 fold more potent than C127 FL-TFPI.

At line 27, "59-fold" has been corrected to read "86-fold".

At lines 26 - 27, added wording sets forth the potency of an additional example of a Kunitz inhibitor alone, C127 CT-TFPI, with a potency of 19-fold (less active than C127 FL-TFPI). The added description is merely consistent with the application as originally filed, which lists comparable relative potencies for other Kunitz inhibitors TFPII-160, and 6L15.

At page 22, Table 1, line 20, "6.3" is amended to read "3.6", and at line 27, "0.017" is amended to read "0.012".

Applicant has provided the replacement Figure 2 which corrects a clerical error in the length of the fusion protein identified as ANV-6L15. As clearly set forth in the application at page 19, line 15, the correct length for ANV-6L15 is 378 amino acids, not 379 amino acids. Replacement Figure 2 corrects the obvious error.

Applicant has also provided a replacement Sequence Listing. The obvious error is in the nucleotide sequence listed for SEQ. ID. NO. 5 wherein the sequence for the fusion gene of human-derived ANV with TAP incorrectly lists another disclosed sequence, SEQ.NO. ID. NO. 8, which is the correct nucleotide sequence for the fusion gene of human-derived ANV with KK-TFPI.

The error is obvious because the application contains numerous written indications that the Sequence Listing as filed is clearly not what Applicant intended to file, and anyone would immediately realize that that Applicant could only have intended what is now offered as rectification of SEQ. ID. NO. 5.

Specifically, the application clearly and correctly sets forth a protein sequence for the fusion protein ANV with TAP(SEQ. ID. NO. 1) which is inconsistent with the nucleotide sequence originally listed under SEQ. ID. NO. 5. SEQ. ID. No. 5 as filed with the application is merely identical to SEQ. ID. No. 8 as filed, which is inconsistent with the remainder of the application. The application clearly distinguishes both the fusion genes themselves, and the gene products of SEQ. ID. NO. 5 and SEQ. ID. NO. 8. Still further, SEQ. ID. NO. 5 as originally listed is inconsistent with the synthetic ala-TAP gene (SEQ. ID. NO. 22) and primer sequences (SEQ. ID. NOS. 34 - 37) which the application clearly explains are used to make the fusion gene for ANV with TAP.

In contrast, the sequence listing for SEQ. ID. NO. 5 now submitted for rectification is completely consistent with the written application and particularly with SEQ. ID. NO. 1,

the correct fusion protein sequence for the product of SEQ. ID. NO. 5.

CONCLUSION

The remarks and amendments made herein shall not be understood or interpreted to disclaim or limit the scope of the claims in any way except as narrowly identified herein.

Should any fees be due for this submission, authorization is hereby given to charge Deposit Account No. 19-3140.

Respectfully submitted,

SONNENSCHEIN NATH & ROSENTHAL LLP

By: _____

Tara A. Nealey, Ph.D.
Registration No. 42,927
Customer No. 26263
314.259.5867

23159696\V-1